BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34345016)

  • 1. Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
    García-Domínguez DJ; Hajji N; Sánchez-Molina S; Figuerola-Bou E; de Pablos RM; Espinosa-Oliva AM; Andrés-León E; Terrón-Camero LC; Flores-Campos R; Pascual-Pasto G; Robles MJ; Machado I; Llombart-Bosch A; Magagnoli G; Scotlandi K; Carcaboso ÁM; Mora J; de Álava E; Hontecillas-Prieto L
    Oncogene; 2021 Sep; 40(39):5843-5853. PubMed ID: 34345016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex.
    Mo J; Tan K; Dong Y; Lu W; Liu F; Mei Y; Huang H; Zhao K; Lv Z; Ye Y; Tang Y
    Oncogene; 2023 Jan; 42(1):11-25. PubMed ID: 36357572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
    Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
    Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
    J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
    Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
    Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.
    Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y
    Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
    Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
    Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.
    Gierisch ME; Pedot G; Walser F; Lopez-Garcia LA; Jaaks P; Niggli FK; Schäfer BW
    Sci Rep; 2019 Jan; 9(1):951. PubMed ID: 30700749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.
    Dallmayer M; Li J; Ohmura S; Alba Rubio R; Baldauf MC; Hölting TLB; Musa J; Knott MML; Stein S; Cidre-Aranaz F; Wehweck FS; Romero-Pérez L; Gerke JS; Orth MF; Marchetto A; Kirchner T; Bach H; Sannino G; Grünewald TGP
    Cell Death Dis; 2019 Feb; 10(2):116. PubMed ID: 30741933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.
    Sánchez-Molina S; Figuerola-Bou E; Blanco E; Sánchez-Jiménez M; Táboas P; Gómez S; Ballaré C; García-Domínguez DJ; Prada E; Hontecillas-Prieto L; M Carcaboso Á; Tirado ÓM; Hernández-Muñoz I; de Álava E; Lavarino C; Di Croce L; Mora J
    Sci Adv; 2020 Oct; 6(43):. PubMed ID: 33097530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
    Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
    J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
    Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
    Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.
    Grünewald TG; Bernard V; Gilardi-Hebenstreit P; Raynal V; Surdez D; Aynaud MM; Mirabeau O; Cidre-Aranaz F; Tirode F; Zaidi S; Perot G; Jonker AH; Lucchesi C; Le Deley MC; Oberlin O; Marec-Bérard P; Véron AS; Reynaud S; Lapouble E; Boeva V; Rio Frio T; Alonso J; Bhatia S; Pierron G; Cancel-Tassin G; Cussenot O; Cox DG; Morton LM; Machiela MJ; Chanock SJ; Charnay P; Delattre O
    Nat Genet; 2015 Sep; 47(9):1073-8. PubMed ID: 26214589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
    McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
    Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.